Hey vault crew —
In 2024–2025, EU member states tightened enforcement on compounded peptide preparations operating outside licensed drug frameworks. France's ANSM, Germany's BfArM, and the UK's MHRA each issued guidance or updated regulations that substantially reduced the legal supply of research peptides through pharmacy compounding channels — reflecting a broader European pharmaceutical compliance push and stricter application of the EU Falsified Medicines Directive.
Compounds covered in this article
THE EU REGULATORY BACKDROP
European peptide compounding sits at the intersection of two frameworks: the EU Falsified Medicines Directive (Directive 2011/62/EU) and member-state pharmacy law. The FMD, strengthened in 2019 with serialization and traceability requirements, created stricter controls on which API (active pharmaceutical ingredient) sources can legally move through the supply chain. While compounding itself remains a member-state matter, the FMD significantly restricts which API sources are permissible — most research-grade peptide suppliers cannot meet its traceability requirements.
The net effect is structural: European compounding pharmacies that relied on Asian or US-sourced peptide APIs now face sourcing constraints that effectively block them from continuing those preparations. The regulatory pressure is supply-side, not prescription-side.
FRANCE AND GERMANY: TIGHTENING THE COMPOUNDING PATHWAY
France's ANSM issued enforcement guidance in Q3 2024 specifically addressing peptide preparations marketed through wellness clinics and compounding pharmacies without a licensed medicinal product basis. BPC-157 and TB-500 were explicitly flagged as lacking the clinical data required to justify compounding under French pharmacy law. Pharmacies must now demonstrate clinical necessity and the absence of an equivalent licensed medicine — a bar these compounds cannot meet.
Germany's BfArM updated its interpretation of the Apothekenbetriebsordnung in early 2025 to require EU GMP certification for all APIs used in compounding. The vast majority of research peptide suppliers do not hold EU GMP certification, effectively blocking their use in German pharmacies regardless of the peptide compound itself.
UNITED KINGDOM: MHRA GUIDANCE POST-BREXIT
Operating under the Human Medicines Regulations 2012, the UK's MHRA issued updated guidance on 'specials' (unlicensed medicines) in 2025 clarifying that peptide compounds without a comparable licensed product may only be supplied on a named-patient basis with documented clinical justification. GH secretagogues including CJC-1295 and Ipamorelin fall under Schedule 4 of the Misuse of Drugs Act 1971 when used for performance enhancement — further restricting their supply pathway.
Legal access to research peptides through European compounding channels has materially narrowed across all three jurisdictions. Users currently sourcing through European clinics should verify current legal status in their specific country. The regulatory trend across the EU and UK is toward further tightening as enforcement infrastructure matures.
Sources & References
